Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|June 1, 2002
- Pharmaceutical Technology-06-02-2002
- Volume 26
- Issue 6
Excipient GMP Quality Standards: One is Enough
Author(s)Irwin Silverstein, PhD
A new set of proposed GMP standards for excipents may present more problems than benefits.
Advertisement
Articles in this issue
over 24 years ago
The IPEC-Americas Excipient Master File Guideover 24 years ago
Technology Advances Anticounterfeiting Optionsover 24 years ago
Calibration of Lyophilization Pressure Gaugesover 24 years ago
Drug Shortages Reveal GMP Concernsover 24 years ago
Outsourcing Outlookover 24 years ago
Optimizing Cross-Organizational Team Performance and Managementover 24 years ago
Screening for Counterfeit Drugs Using Near-Infrared Spectroscopyover 24 years ago
Building on Tradition: Integrating the Links of ExpertiseAdvertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement